Great, youve already taken the first step
We may be able to re-start the medication at a lower dose
Indications: Obesity (BMI 30 kg/m) Overweight (BMI 27 kg/m) with weight-related comorbidities Should be used with dietary and physical activity interventions Contraindications: Hypersensitivity to semaglutide or excipients Pregnancy or breastfeeding Personal/family history of medullary thyroid carcinoma Diagnosis of MEN 2 Side Effects: Very common (10%) : Nausea, vomiting, diarrhea, constipation Common (110%) : Headache, dizziness, fatigue, reflux Less common/rare : Gallstones, pancreatitis, renal impairment Reports of suicidal ideation in post-market surveillance Each pen delivers 2.4 mg of semaglutide in 0.5 mL of clear, colorless solution
When to Speak with Your GP About GLP-1 You should arrange an appointment with your GP if you are experiencing persistent symptoms that may indicate metabolic dysfunction, regardless of whether they relate specifically to GLP-1
Any NDA or BLA submission is anticipated only after Phase 3 completion and regulatory review
This service is billed using CPT code 93015